Zhuo et al. demonstrated that PCIF1 promoted the proliferation and invasion of gastric cancer by targeting TM9SF1.[12] In colorectal cancer, Wang et al. indicated PCIF1 is indispensable for tumorigenesis and can be targeted to enhance the efficacy of immunotherapy.[13] A recent study reported that PCIF1 binds to its cofactor CTBT2, contributing jointly to the development of head and neck squamous cell carcinoma.[50] Despite these advancements, the role of m6Am in RCC remains poorly understood, even though RCC progression was recognized to be closely linked to epigenetic dysregulation. The gene discussed is TM9SF1; the disease is colorectal cancer.